OncoVista Innovative Therapies, Inc. (OVIT) Stock Price & Analysis
Educational signal · not a buy or sell recommendation · How to read this
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 16, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerOncoVista Innovative Therapies, Inc. (OVIT) trades at $0.0001. OncoVista Innovative Therapies, Inc. is a biopharmaceutical company focused on developing targeted anticancer therapies using tumor-associated biomarkers. Sector: Healthcare.
Price as of · Last analyzed: Mar 16, 2026Analyst Coverage for OVIT: OVIT does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage.
No score published: we hold no usable price for this ticker, and a grade beside a missing price says nothing.
OncoVista Innovative Therapies, Inc. (OVIT) Healthcare & Pipeline Overview
OncoVista Innovative Therapies, Inc. is a biotechnology firm specializing in targeted anticancer therapies, with a focus on tumor-associated biomarkers. Their pipeline includes OVI-123, currently in Phase I/II trials for leukemia, and OVI-117, a pre-clinical treatment for colon cancer, positioning them in the competitive oncology therapeutics market.
What Is the Investment Thesis for OVIT?
OncoVista Innovative Therapies presents a high-risk, high-reward investment opportunity within the biotechnology sector. The primary value driver is the successful development and commercialization of its lead drug candidate, Cordycepin (OVI-123), currently in Phase I/II clinical trials. Positive clinical trial data could significantly increase the company's valuation. The pre-clinical development of OVI-117 for colon cancer also represents a potential growth catalyst. However, the company's small size, limited resources, and reliance on a single lead product candidate create significant risks. Investors should closely monitor clinical trial results, regulatory milestones, and the company's ability to secure additional funding. The negative beta of -45.23 suggests an inverse correlation with the market, which may provide some downside protection during market downturns.
Based on FMP financials and quantitative analysis
OVIT Key Highlights
Cordycepin (OVI-123) is in Phase I/II clinical trials for the treatment of refractory TdT positive leukemias, representing a key milestone in the company's development.
- L-Nucleoside Conjugates (OVI-117) are under pre-clinical development for the treatment of colon cancer, expanding the company's pipeline.
- The company was founded in 2004, indicating over two decades of experience in the biopharmaceutical industry.
- OncoVista Innovative Therapies operates with a small team of 2 employees, reflecting a lean operational structure.
- The company's focus on tumor-associated biomarkers positions it within the growing field of personalized medicine.
Who Are OVIT's Competitors?
OVIT is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| POM Pomdoctor Limited | $0.93 | +8.13% | $6.30M | 34 5-pillar |
| MEDS TRxADE HEALTH, Inc. | $3.35 | -8.97% | $8.79M | — |
| MSLE Satellos Bioscience Inc. Common Stock | $8.05 | -5.29% | $11.0M | 33 5-pillar |
| NEUP Neuphoria Therapeutics Inc. | $3.45 | -0.58% | $18.7M | — |
| AIXC AIxCrypto Holdings, Inc. | $1.01 | -39.16% | $20.4M | — |
| RNTX Rein Therapeutics, Inc. | $0.82 | +3.03% | $23.1M | — |
| KYNB Kyntra Bio, Inc. | $6.09 | -3.49% | $24.7M | — |
| YI 111, Inc. | $3.15 | -2.17% | $28.1M | 39 5-pillar |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are OVIT's Key Strengths?
Proprietary technology targeting tumor-associated biomarkers.
- Lead product candidate in Phase I/II clinical trials.
- Focus on unmet medical needs in refractory cancers.
- Experienced management team with expertise in drug development.
What Are OVIT's Weaknesses?
Limited financial resources.
- Small team with only 2 employees.
- Reliance on a single lead product candidate.
- OTC market listing may limit access to capital.
What Are the Key Risks for OVIT?
Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
- Failure to secure additional funding to support clinical trials.
- Negative clinical trial results for OVI-123 or OVI-117.
- Regulatory delays or rejection of drug candidates.
- Competition from larger pharmaceutical companies with greater resources.
- Risks associated with trading on the OTC Other market.
What Are OVIT's Competitive Advantages?
- Proprietary technology based on tumor-associated biomarkers.
- Patent protection for its drug candidates.
- Clinical trial data demonstrating the efficacy and safety of its therapies.
- Expertise in targeted cancer therapy development.
What Does OVIT Do?
Founded in 2004 and based in San Antonio, Texas, OncoVista Innovative Therapies, Inc. is a biopharmaceutical company dedicated to the development of targeted anticancer therapies. The company leverages tumor-associated biomarkers to create more effective and personalized treatments for cancer patients. OncoVista's lead product candidate is Cordycepin (OVI-123), which is currently undergoing Phase I/II clinical trials for the treatment of refractory TdT positive leukemias. This therapy represents a significant step towards addressing the unmet needs of patients with this aggressive form of leukemia. In addition to OVI-123, OncoVista is also developing L-Nucleoside Conjugates (OVI-117), a pre-clinical program focused on the treatment of colon cancer. The company's research and development efforts are centered on identifying and exploiting unique characteristics of cancer cells to develop therapies that are both effective and less toxic than traditional chemotherapy. OncoVista Innovative Therapies operates with a small team, emphasizing focused research and strategic partnerships to advance its pipeline.
What Products and Services Does OVIT Offer?
- Develop targeted anticancer therapies.
- Utilize tumor-associated biomarkers to identify and target cancer cells.
- Conduct clinical trials to evaluate the safety and efficacy of its drug candidates.
- Focus on developing therapies for refractory cancers with unmet medical needs.
- Advance pre-clinical programs for the treatment of various types of cancer.
- Seek strategic partnerships to accelerate drug development and commercialization.
How Does OVIT Make Money?
- Develop and patent novel anticancer therapies.
- Conduct pre-clinical and clinical research to validate the efficacy and safety of their therapies.
- Out-license or partner with larger pharmaceutical companies for commercialization.
- Potentially generate revenue through milestone payments and royalties on partnered products.
What Industry Does OVIT Operate In?
OncoVista Innovative Therapies operates within the biotechnology industry, a sector characterized by high innovation, intense competition, and significant regulatory hurdles. The global biotechnology market is projected to reach $3.44 trillion by 2030, driven by advancements in genomics, personalized medicine, and targeted therapies. OncoVista's focus on tumor-associated biomarkers aligns with the trend towards more precise and effective cancer treatments. Competitors include larger pharmaceutical companies and specialized biotech firms, such as ANTH, COTQF, FORU, LPTI, and NEWG, all vying for market share in the oncology therapeutics space.
Who Are OVIT's Key Customers?
- Patients with refractory TdT positive leukemias.
- Patients with colon cancer.
- Pharmaceutical companies seeking to in-license or acquire novel cancer therapies.
- Healthcare providers who prescribe cancer treatments.
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● No usable price
- ● No filing on record
- ● No analyst coverage
Company Profile
OncoVista Innovative Therapies, Inc. operates in the Healthcare sector. It is headquartered in San Antonio, US. The company is led by CEO Alexander L. Weis. OVIT has traded publicly since 2007.
Key Financial Metrics
Return on equity for OncoVista Innovative Therapies, Inc. stands at 57.9%, a gauge of how efficiently it converts shareholder capital into profit. A current ratio of 0.00 means current liabilities exceed short-term assets, a liquidity point worth watching.
Financial Health
OncoVista Innovative Therapies, Inc.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
OVIT Financials
OVIT Latest News
No recent news available for OVIT.
OVIT Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for OVIT.
Price Targets
Wall Street price target analysis for OVIT.
OVIT MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for OVIT; grades run from A+ (80-100) to F (below 30).
Leadership: Alexander L. Weis
CEO
Alexander L. Weis serves as the CEO of OncoVista Innovative Therapies, Inc. His background includes experience in managing small teams and guiding the strategic direction of the company.
Track Record: As CEO, Alexander L. Weis has overseen the development of Cordycepin (OVI-123) through Phase I/II clinical trials. His leadership has been instrumental in securing funding and partnerships to support the company's research and development efforts. He manages a small team of 2 employees, focusing on lean operations and strategic decision-making.
OVIT OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that OncoVista Innovative Therapies may not meet the minimum financial or reporting requirements of higher tiers like OTCQX or OTCQB. Companies on the OTC Other tier may have limited regulatory oversight and may not be required to provide audited financial statements. This tier is often associated with higher risk and greater potential for volatility compared to companies listed on major exchanges like the NYSE or NASDAQ. Investors should exercise caution and conduct thorough due diligence before investing in companies on the OTC Other tier.
- OTC Tier: OTC Other
- Limited regulatory oversight and disclosure requirements.
- Low trading volume and liquidity.
- Potential for price manipulation and volatility.
- Higher risk of fraud or mismanagement.
- Difficulty in obtaining reliable financial information.
- Verify the company's legal status and registration.
- Attempt to obtain and review audited financial statements.
- Assess the company's management team and their track record.
- Research the company's products and services and their market potential.
- Evaluate the company's competitive landscape.
- Monitor trading volume and price activity for signs of manipulation.
- Consult with a qualified financial advisor.
- Company has been in operation since 2004.
- Development of drug candidates in clinical trials.
- Focus on targeted cancer therapies.
- Presence of a CEO and management team.
OVIT Healthcare Stock FAQ
What revenue streams does OncoVista Innovative Therapies, Inc. have in healthcare?
Currently, OncoVista Innovative Therapies, Inc. does not have established revenue streams as it is in the clinical and pre-clinical stages of drug development.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
MoonshotScore is not published for this security.
Data provided for informational purposes only.
- Limited information available on the company due to its OTC listing and small size.
- Financial data is not readily available.